Cachexia is a complex, multiorgan phenomenon targeting skeletal muscle resulting from systemic metabolic imbalances. Multifocal in nature, its ultimate outcome is significant muscle degradation and loss of adipose tissue exhibited as the “wasting syndrome” which is associated with significant functional decline. Currently, there are no approved biomarkers for screening nor therapeutic options to manage cancer cachexia. Furthermore, multiple psychosocial sequelae characterize the patient and family coping paradigm. Heightened education about the pathophysiology of cancer cachexia and awareness of intra-familial emotional distress can enhance oncology nurses’ advocacy about, and attentiveness to, this common manifestation of advanced cancer.

**Key word:** Cachexia, eating, food conflict, muscle wasting, weight loss

**Introduction**

A distinguishing feature of solid tumors is their propensity to metastasize. This extension of cancerous cells beyond the site of initial growth is the cause of death in the majority of patients who die from cancer. Cancer cachexia is a common corollary of advanced cancer due to its molecular linkage with the metastatic process. It is often overlooked and rarely controlled. Consider the following facts. Cachexia occurs in:

- More than 50% of patients with liver, pancreas, lung, head and neck, gastric, and colorectal primary tumors
- 50%–80% of patients with advanced cancer; and
- Greater than 80% of patients in their last weeks of life.

In addition, cachexia is responsible for 20% of deaths from cancer related to cardiac arrhythmias, hypoventilation, thromboembolic events, cardiorenal dysfunction, and/or a compromised immune system. Other negative corollaries of cachexia include an association with reduced efficacy of antineoplastic therapies, enhanced treatment toxicity, heightened incidence of surgical complications, and decreased overall survival.

**Pathogenesis**

The term “Cachexia” has Greek origins, namely “Kakos” and “Hexis” meaning “Bad Condition.” This multigran syndrome is prompted by reduced food intake and metabolic dysregulation (i.e., elevated energy expenditure, excess catabolism, inflammation) that triggers skeletal muscle loss. Anorexia or the reduced desire for food (i.e., loss of appetite) results from the impaired central nervous system (CNS) triggering due to presence of tumor byproducts and/or immune responses to the tumor. Chemotherapy may also be an etiology due to CNS anorectic effects that evolve through neuronal dysregulation.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Cite this article as: Boyle DA. Contemporary Insights into Cancer Cachexia for Oncology Nurses. Asia Pac J Oncol Nurs 2021;8:462-70.
in the hypothalamus. Other causes of altered food intake may be present and contribute to anorexia particularly in patients with advanced disease [Table 1].

An oncologic paraneoplastic syndrome, cancer cachexia is a complex disorder marked by excessive catabolism which causes alterations in lipid, protein, and carbohydrate metabolism, systemic inflammation, and insulin resistance. It's manifestations include involuntary weight loss evidenced in skeletal muscle, adipose tissue, the heart, intestine, kidney, liver, and brain. The tumor is the principle prompt of metabolic reprogramming that leads to the objective presentation of the “wasting” phenomenon. Skeletal muscle and adipose tissue are the primary targets throughout cancer cachexia’s progression. While muscle atrophy is the most obvious manifestation of cachexia, multiple organ dysfunctions are co-occurring subclinically [Figure 1].

Skeletal muscle is one of the most metabolically active tissue lines and serves as a repository of protein and amino acids. Its contraction requires considerable energy to function optimally. Muscle mass loss evolves due to an imbalance between anabolic and catabolic processes. Of note is that human skeletal muscle represents 40% of body weight and that once muscle mass has been impaired from cachexia, it has limited capacity for regeneration. The combination of muscle degradation with atrophy and the concomitant loss of adipose tissue ultimately leads to progressive overall functional decline. Elderly cancer patients may exhibit more profound cachexia due to reduced muscle mass associated with aging. The enhanced lipid breakdown in white adipose tissue may also cause a browning discoloration of the skin which usually is indicative of cachexia’s progression.

Cardiac Implications of Cancer Cachexia

While skeletal muscle mass and adipose tissue are primary targets of cachexia, other organs such as the heart may experience damage. It is estimated that 20%–30% of cancer patients die from cardiovascular causes. Of note, is evidence of symptom presentation in patients with advanced cancer correlating with heart failure (i.e., shortness of breath, pulmonary congestion, decreased mobility and performance status, sudden death). While historically these symptoms have been considered an end-product of disseminated cancer, they may in fact characterize a degenerative form of cardiomyopathy.

Numerous cellular wasting processes may impact the structure and functioning of cardiac conduction pathways ultimately resulting in heightened arrhythmia risk. In a sequential manner, cardiac atrophy leads to impaired cardiac contractility and reduced heart rate. In addition, cancer-induced metabolic alterations may affect insulin and glucose metabolism, and iron uptake which can also affect cardiac and skeletal muscle function. Impaired cardiac innervation and blood hyper-coagubility may also play a role in increased cancer-related mortality. Hence, the sudden death of a patient with advanced cancer may be precipitated by cardiac dysfunction resulting from the loss of skeletal muscle mass. Debilitation in respiratory muscle function may exacerbate cardiac compromise.

As the field of cardio-oncology evolves, future approaches to cachexia management may include the evaluation of patient functional status and biomarker-driven evidence of cardiac muscle wasting to consider the prophylactic use of defibrillators. This in concert with the administration of potentially cardio-toxic antineoplastics (i.e., anthracycline agents) and irradiation to the left chest needs to be considered in risk evaluation. A contemporary increase in knowledge about cachexia’s manifestations in the heart’s functioning has led to the naming of a parallel entity called “Cardiac cachexia.”

Screening, Staging, and Assessment

Involuntary weight loss in a cancer patient is generally overlooked and rarely managed in an aggressive manner.

Table 1: Etiologies of altered food intake

| Food aversions | Consistency | Smell | Taste |
|----------------|-------------|------|------|
| Appetite changes | Absence of appetite trigger | Early satiety |
| Functional difficulties | Dry mouth | Dysphagia | Esophagitis |
| Indigestion/heartburn | Mucositis |
| Bowel alterations | Bloating | Constipation | Diarrhea |
| Mood disturbances | Depression |
| Co-occurring symptoms | Drowsiness | Fatigue | Insomnia |
| Nausea | Pain | Shortness of breath |

Figure 2 depicts cancer-associated cardiac consequences with potential adverse corollaries.
Yet, it is a hallmark symptom of cachexia’s presence and often a predictor of reduced survival. Once a patient experiences weight loss equal to or more than 5% of their usual weight, they already are at risk for increased mortality.\(^{[30]}\)

**Screening**

Computerized tomography (CT) or magnetic resonance imaging (MRI) is the first choice for analyzing body composition. CT or MRI of the lumbar spine (L3) are preferred as both skeletal muscle and adipose tissue in this region correspond to whole-body dimensions.\(^{[5]}\) Of note is that this landmark is present in routine abdominal CT scans precluding the need for additional radiologic evaluation.\(^{[31]}\) Ideal muscle depletion parameters include those identified at the L3 site and anthropometric mid-arm circumference [Table 2].\(^{[18]}\)

To date, there have been no approved clinical biomarkers for cancer cachexia. However, their future identification will be increasingly instrumental in cachexia’s early recognition. Potential biomarkers are classified as those originating from the host (i.e., cachexia-inducing factors, muscle, and fat wasting products), the tumor (i.e., tumor-necrosis factor), and both host and tumor (i.e., inflammatory cytokines, micro RNAs).\(^{[14]}\) Bruggeman et al.\(^{[31]}\) noted that the combination of elevated C-reactive protein, weight loss, and nutritional intake, may be used in the future as a combined measure of cachexia. Other imminent biomarkers may include the presence of increased inflammatory cytokines (i.e., interleukin 6, tumor necrosis factor), urine levels of lipid mobilizing factor, and interleukins identified in tissue biopsy samples.

**Staging**

Cancer cachexia is conceptualized as a continuum, distinguished by three stages: Pre-cachexia, cachexia, and refractory cachexia.\(^{[8,32-35]}\) Figure 3 depicts characteristics of each stage. Of note, is that by the time cachexia is clinically recognized (i.e., stage 2), it usually is resistant to interventions; yet these patients have been the most studied to date.\(^{[31,37]}\)

Pre-cachectic patients will be the targeted focus of study in the future. Metabolic abnormalities precede weight loss during this phase and patients often maintain their usual functional status. Monitoring these
They not only do not address the multisystem pathways associated with this clinical syndrome.\(^9,11,12\) Figure 4 identifies agents used to manage the sequelae of cachexia; specifically to improve appetite, regulate inflammatory responses, and mediate anabolic and catabolic processes. Contemporary investigational drugs based on their mechanism and site of action are highlighted in Figure 5.

The efficacy of other non-regulated interventions should be questioned. Artificial nutrition and hydration are not indicated in refractory cachexia.\(^{13}\) They not only do not improve survival but also are correlated with potential vomiting/regurgitation and aspiration.\(^{15}\) Currently, there are no evidence-based results supporting the use of cannabis.\(^{15}\) However, in the future setting of randomized controlled trials with purposeful choice of cannabis extract (i.e., natural vs. synthetic derivative) and more rigorous dose scheduling, future research may reveal efficacy.\(^{18}\) Megestrol acetate (i.e., Megace) for appetite stimulation is the only FDA-approved for use in AIDS-associated cachexia.\(^{19}\) The absence of indications in other illnesses stem from research findings that weight gain appears to be related to an increase in body fat and fluid retention without gain in lean body mass.\(^{22}\) In addition, a concern about the use of Megace acetate in cancer patients also is associated with its red box warning about potential thromboembolic events.\(^{19}\)

Nearly all the clinical trials to date have focused on pharmacologic interventions and have not integrated behavioral or psychosocial therapies.\(^{22,48}\) Potential benefits of exercise include positive modulation in protein expression, improvement in aerobic capacity, and conservations of skeletal muscle mass with improved muscle function.\(^{12,18}\) A focus on nutrition therapy could potentially enhance the provision of energy fuels with protein-rich formulations to maximally support muscle mass and anabolism.\(^{41}\) Such therapies could interfere with the crescendo of catabolic stimuli such as muscle catabolic signaling. In the future, consideration of diet, exercise, adherence to nutritional therapies, and psychosocial counseling will most likely be researched within a paradigm of multidisciplinary approach.\(^{31,42,43}\) A prototype for combined, multidisciplinary therapy is the Multimodal-Exercise, Nutrition and Anti-Inflammatory medication for Cachexia trial.\(^{44}\) In the meantime, the American Society of Clinical Oncology has published evidence-based guidelines for the current management of cancer cachexia which are outlined in Table 3.\(^{45}\)

### Table 2: Quantification of muscle depletion\(^{18}\)

| Site                  | Men    | Women   |
|-----------------------|--------|---------|
| L3 (cm\(^2\)/m\(^2\)) | <55    | <39     |
| Mid-arm circumference (cm) | <32    | <18     |

### Measurement instruments

In addition to laboratory findings, biomarkers, body mass index, and weight loss, subjective reports of quality of life, functional status, anxiety, depression, appetite, anorexia, family distress, and caregiver burden have also been reported as outcome measures. Instruments often used within the context of clinical trials include the 12-item Functional Assessment of Anorexia/Cachexia Treatment, and the EORTC health-related quality of life, cachexia symptom-focused QLQ-CAX 24.\(^{31,36}\) Future outcome indices may include patient and family satisfaction, functional status identified through pedometer reading, morphometrics, novel biomarkers, and muscle mass (not just body mass index) especially if exercise and nutrition interventions are integrated early into the treatment paradigm.

### Therapeutic Approaches

Currently, there is no established standard of care to manage cancer cachexia nor an Food and Drug Administration (FDA)-approved drug to treat it.\(^{14,18}\) Numerous issues to date are associated with this unfortunate reality. They include targeting interventions that focus on patients with refractory cachexia who are not amenable to treatment.\(^{31}\) Small sample size and inconsistent use of outcomes measures are other problems.\(^{10}\) Furthermore, the historical management of cancer cachexia has used a single-agent, “Magic Bullet” approach which does not address the multisystem pathways associated with this clinical syndrome.\(^9,11,12\) Figure 4 identifies agents used to manage the sequelae of cachexia; specifically to improve appetite, regulate inflammatory responses, and mediate anabolic and catabolic processes. Contemporary investigational drugs based on their mechanism and site of action are highlighted in Figure 5.

The pervasive emotive response of sustained helplessness generated by cancer cachexia has been termed the “Weight...
loss taboo” which is experienced by patients, their caregivers, and health care professionals.\textsuperscript{46} For patients, cachexia prompts distress emanating from alterations in self-image, self-esteem, and socialization norms.\textsuperscript{47} Even embarrassment over one’s appearance and debility may prevail.\textsuperscript{48} Refractory cachexia is a visible sign of cancer’s progression. It is a persistent reminder to patients and those around them that they are declining, not recovering. Cachexia makes the disease visible, indicating the proximity of disease progression and likely death.\textsuperscript{23} With functional decline also comes increased dependence on others, much feared consequence of life-threatening illness. Reliance on caregivers often encompasses meal preparation, assistance with basic needs, and transportation, all of which are associated with the perception of being a burden.\textsuperscript{49} Hence, due to the magnitude of negative corollaries, minimizing negative corollaries, and the patient’s focus on minimizing eating problems is common.

There is growing evidence that caregivers exhibit more distress than patients within the context of cancer cachexia.\textsuperscript{50} Much of this intra-familial discord focuses on the erroneous perception that increased eating will increase survival.\textsuperscript{5} Additionally, alterations in eating norms influence communication exchange within the family. Since eating and dining are common social events, changes in these patterns often leave loved ones feeling isolated and distraught. Family members often experience feelings of futility related to the energy they assert in food preparation and rejection while watching patient waste away.\textsuperscript{51} Family caregivers often view their primary role...
as nourishing their family, thus when impediments to this responsibility evolve, they may experience a sense of failure, even shame. Cultural considerations about the role of food in illness also must be considered. In many Asian cultures, for example, food intake and enhancing feeding are perceived as mechanisms of showing hope, care, love, and respect. Within the context of cancer cachexia, Amano identified eight items that cause the most distress in family caregivers:

- I want attention to be paid to my distress about the patient’s eating
- I feel that a lack of nutrition makes the patient’s condition worse
- I wonder what kinds of food the patient can eat
- I wonder which nutrients the patient should preferentially consume
- I wonder how the patient can eat more
- I feel more medical support about the patient’s daily diet is needed
- I feel that the patient disregards the effort that I show by making his/her meals
- I feel sad because the patient cannot enjoy dinner with me.

Conflict over food may become the norm and evolve into an issue of control, representative of a clash between the family caregiver taking charge and the patient struggling to maintain a sense of autonomy. For the patient, meals no longer bring pleasure but herald conflict, and at most, represent basic survival. Table 4 summarizes the varied elements of intra-familial food-related distress and supports the opinion that psychosocial interventions need to be a mainstay of family-centered care within this construct.

Finally, there are food-associated stressors associated with the patient and family’s interaction with the cancer care team. In particular, family caregivers experience frustration about the team’s lack of recognition of cachexia as a problem. The failure to discuss or question the presence and prominence of this syndrome leaves the family feeling ill-equipped in knowing how to manage this problem. Dewey and Dean research identified that nurses offered suggestions for maximizing calorie and protein intake but only after the patient and/or family asked for assistance. The lack of a distinct management approach to cancer cachexia was indicative of a culture of avoidance which was especially troubling to caregivers.

### Implications for Oncology Nurses

There are numerous ramifications for nursing within the realm of cancer cachexia. For patients with advanced disease at diagnosis, cancer cachexia may be present along the entire illness trajectory. Nurses working in sub-specialties of gastrointestinal, pulmonary, and radiation oncology need to have a sophisticated understanding of cachexia and screening guidelines in place. The Malnutrition Screening Tool is a validated, brief, user-friendly instrument to determine the risk for malnutrition in cancer care. Ideally this tool should be used sequentially with patients ultimately screening positive for risk being referred to registered diabetics. Built-in prompts in the electronic medical record can facilitate screening compliance.

An interdisciplinary team is ideally required to optimize the multifaceted management of this complex syndrome. In the absence of such, lobbying for consultation by these colleagues is indicated. Having the closest and continued proximity with patients also affords oncology nurses opportunities to identify research questions. Several issues that require study include interventions to optimize adherence to therapy recommendations, elucidating stage-specific distress themes of relevance, managing the sequelae of cachexia within patient/family dyads, and determining if the magnitude of weight loss is correlated with caregiver distress.

### Conclusions

Nutrition is an important component of cancer care to many patients and family caregivers. Engaging in dietary

---

**Table 3: Synopsis of major recommendations of the American Society of Clinical Oncology guidelines for Nutritional and Pharmacological Interventions in the Management of Cancer Cachexia**

| Intervention category | Recommendation |
|-----------------------|----------------|
| Nutritional           | Clinicians may refer patients with advanced cancer and loss of appetite and/or body weight to a registered dietician for assessment and counseling, with the goals of providing patients and caregivers with practical and safe advice for feeding; education regarding high protein, high caloric, nutrient dense food; and advice against fad diets and other unproven or extreme diets. Outside the context of a clinical trial, clinicians should not routinely offer enteral tube feedings or parenteral nutrition to manage cachexia in patients with advanced cancer. |
| Pharmacologic         | Evidence remains insufficient to strongly endorse any pharmacologic agent to improve cancer cachexia outcomes; there are currently no FDA-approved medications for the indication of cancer cachexia. Clinicians may offer a short-term trial of a progesterone analog or a corticosteroid to patients experiencing loss of appetite and/or body weight. |
| Other                 | Outside the context of a clinical trial, no recommendations can be made for other interventions such as exercise for the management of cancer cachexia. |

**FDA:** Food and drug administration

---
Cachexia is not simply a nutritional aberrancy. Rather, it is a common, complex, and usually lethal multiorgan disorder with no effective therapies. Due to its poor prognosis and considerable influence on patient and caregiver distress, cancer cachexia is representative of the phenomenon of suffering. Nutrition is an important component of cancer care to many patients and family caregivers. Engaging in dietary interventions represents an enhanced sense of personal control in managing cancer. Yet, professionals’ lack of awareness of the importance of this component of patient care in tandem with minimal resourcing of clinical dieticians, often positions nutrition support as an unmet need.

Cachexia requires more deliberate education about this syndrome. Increased knowledge can leverage frontline oncology nurses to solicit interdisciplinary support to maximize symptom management. Greater professional education can also increase nurses’ awareness about cachexia and help transform a culture of avoidance to one of inclusion by discussing its prominence with patients and families.

This author has noted important corollaries between cancer-related fatigue and cancer cachexia. Historically, fatigue was perceived as a common symptom with no interventions available to address its prominence. Recently, however, this phenomenon has been the focus of considerable research to optimize its management. Similarly, as cachexia’s complex multifocal etiologies become increasingly understood, the possibility for effective management can be anticipated.

In today’s oncology nursing practice environment, the clinical presence of cachexia portends trepidation and often despair in patients and families. An oncology nurse dually skilled in the provision of physical and emotional comfort is needed to enhance living regardless of patient prognosis. Dame Cicely Saunders summed it best with her intuitive historic reflection.

I once asked a man who knew he was dying what he looked for most in the people caring for him. He paused for a moment and said, I look to see if they are trying to help me. Saunders then shared, You see, he did not ask for success, he asked only for the effort of trying.

## Financial support and sponsorship
Nil.

## Conflicts of interest
There are no conflicts of interest.

## References
1. Clezardin P. Pathophysiology of bone metastases from solid tumors. Joint Bone Muscle 2017;84:677-84.
2. Schaller J, Agudo J. Metastatic colonization: Escaping immune surveillance. Cancers (Basel) 2020;12:3385.
3. Dilekñas H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med 2019;8:5574-6.
4. Biswas AK, Acharya S. Understanding cachexia in the context of metastatic progression. Nat Rev Cancer 2020;20:274-84.
5. Granda-Cameron C, Lynch MP. Clinical framework for quality improvement of cancer cachexia. Asia Pac J Oncol Nurs 2018;5:369-76.
6. Advani SM, Advani PG, VonVille HM, Jafri SH. Pharmacological management of cachexia in adult cancer patients: A systematic review of clinical trials. BMC Cancer 2018;18:1174.
7. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: Facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1-5.
8. Buonacorso L, Bertocchi E, Autelitano C, Accogli M, Dentí M, Fugazzaro S, et al. Psychoeducational and rehabilitative...
intervention to manage cancer cachexia (PFICC) for patients and their caregivers: Protocol for a single arm feasibility trial. BMJ Open 2021;11:e042883.

9. Li Y, Jin H, Chen Y, Huang T, Mi Y, Zou Z. Cancer cachexia: Molecular mechanism and pharmacologic management. Biochem J 2021;479:1663-68.

10. Siff T, Parajuli P, Razzaque MS, Afia A. Cancer-mediated muscle cachexia: Etiology and clinical management. Trends Endocrinol Metab 2021;32:382-402.

11. Argilès JM, Busquets S, López-Soriano FJ. Cancer cachexia, a clinical challenge. Curr Opin Oncol 2019;31:286-90.

12. Kim AJ, Hong DS, George GC. Diet-related interventions for cancer-associated cachexia. J Cancer Res Clin Oncol 2021;147:1443-50.

13. Ni J, Zhang L. Cancer cachexia: Definition, staging, and emerging treatments. Cancer Manag Res 2020;12:5597-605.

14. Cao Z, Zhao K, Jose I, Hoogenraad NJ, Osellame LD. Biomarkers for cancer cachexia: A mini review. Int J Mol Sci 2021;22:4501.

15. Mondello P, Mian M, Aloisi C, Famà F, Mondello S, Pittini V. Cancer cachexia syndrome: Pathogenesis, diagnosis, and new therapeutic options. Nutr Cancer 2015;67:12-26.

16. Rausch V, Sala V, Penna F, Porporato PE, Ghigo A. Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. Oncogenesis 2021;10:1.

17. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers 2018;4:17105.

18. Schmidt SF, Rohm M, Herzig S, Berriel-Diaz M. Cancer cachexia: More than skeletal muscle wasting. Trends Cancer 2018;4:849-60.

19. Argilès JM, Busquets S, Stemmber L, López-Soriano FJ. Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer 2014;14:754-62.

20. Siddiqui JA, Pottharjtu R, Jain M, Batra SK, Nasser MW. Advanced in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions. Biochem Biophys Acta Rev Cancer 2020;1873:188359.

21. Molinò A, Amabile MI, Giorgi A, Monti M, D'Andrea V, Muscaritoli M. Investigational drugs for the treatment of cancer cachexia: A focus on phase I and phase II clinical trials. Expert Opin Investig Drugs 2019;28:733-40.

22. Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M, Rezaei N. Cancer cachexia: Diagnosis, assessment, and treatment. Crit Rev Oncol Hematol 2018;127:91-104.

23. Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, Herrstedt J, et al. Early recognition of malnutrition and cachexia in the cancer patient: A position paper of a European School of Oncologic Task Force. Ann Oncol 2014;25:1492-9.

24. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol 2017;28:400-7.

25. Anker MS, Hadzibegovic S, Lean A, Belenkov Y, Bergler-Klein J, de Beer RA, et al. Recent advances in cardio-oncology: A report from the Health Failure Association and World Congress on Acute Heart Failure, 2019. ESC Heart Fail 2019;6:1140-8.

26. Anker MS, Sarz AP, Zamorano JL, Mehra MR, Butler J, Riess H, et al. Advanced cancer is also a heart failure syndrome: A hypothesis. J Cachex Sarcom Muscle 2021;12:533-7.

27. Wyart E, Bindels LB, Mina E, Menga A, Stanga S, Porporato PE. Cachexia, a systemic disease beyond muscle atrophy. Int J Mol Sci 2020;21:8592.

28. Tocchetti CG, Ameri P, de Boer RA, D’Alessandra Y, Russo M, Sorrentino D, et al. Cardiac dysfunction in cancer patients: Beyond direct cardiomyocyte damage of anti-cancer drugs: Novel cardio-oncology insights from the Joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res 2020;116:1820-34.

29. Boyle DA. Cancer and the broken heart: Complications and implications of therapy-Related Cardiotoxicity. J Infus Nurs 2018;41:229-40.

30. Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 2015;33:90-9.

31. Bruggeeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer Cachexia: Beyond Weight Loss. J Oncol Pract 2016;12:1163-71.

32. Kordes M, Larsson L, Engstrand L, Lörh JM. Pancreatic cancer cachexia: Three dimensions of a complex syndrome. Br J Cancer 2021;124:1623-36.

33. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-95.

34. Balstad TR, Solheim TS, Strasser F, Kaasa S, Bye A. Dietary management of weight loss in patients with advanced cancer and cachexia: A systematic literature review. Crit Rev Oncol/ Hematol 2014;91:210-21.

35. Wiegert EV, de Oliveira LC, Calixto-Lima L, Chaves GV, Silva Lopes MS, Peres WA. New cancer cachexia staging system for use in clinical practice. Nutrition 2021;90:11271.

36. Wheelwright SJ, Hopkinson JB, Darlington AS, Fitzsimmons DF, Fayers P, Balstad TR, et al. Development of the EORTC-QLQ-CAX 24, a questionnaire for cancer patients with cachexia. J Pain Symp Man 2017;33:232-42.

37. Kobani A, Dy SM, Gupta A. The key role of nonpharmacological management of cachexia in persons with advanced illness: A teachable moment. JAMA Int Med 2021;26:978-9.

38. Wang J, Yang G, Tong M, Pan H, Li D. New prospect for cancer cachexia: A medical cannabinoid. J Cancer 2019;10:716-20.

39. Garcia V, López-Briz E, Sanchis R, Perales J, Bort-Martí S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Sys Rev 2013;2013:CD004310.

40. Del Fabbro E. Combination therapy in cachexia. Ann Pall Med 2019;8:59-66.

41. Schiessel DL, Baracos VE. Barriers to cancer nutrition therapy: Excess catabolism of muscle and adipose tissues induced by tumour products and chemotherapy. Proc Nutr Soc 2018;77:394-402.

42. Grande AJ, Silva V, Neto LS, Basmage JP, Peccin MS, Maddocks D. Exercice for cancer cachexia in adults. Cochrane Database Sys Rev 2021:3:CD008004.

43. Lee J, Leong LP, Lim SL. Nutrition intervention approaches to reduce malnutrition in oncology patients: A systematic review. Support Care Cancer 2016;24:469-80.

44. Solheim TS, Laird BJ, Balstad TR, Bye A, Stene G, Baracos V, et al. Cancer cachexia: Rationale for the MENAC (multimodal – Exercise, nutrition, and anti-inflammatory medication for cachexia) trial. BMJ Support Palliat Care 2018;8:258-65.

45. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E,
Dixon S, et al. Management of cancer cachexia: ASCO Guideline. J Clin Oncol 2020;38:2438-53.
46. Hopkinson JB. Psychosocial impact of cancer cachexia. J Cachexia Sarcopenia Muscle 2014;5:89-94.
47. Cooper C, Burden ST, Cheng H, Molassiotis A. Understanding and managing cancer-related weight loss and anorexia: Insights from a systematic review of qualitative research. J Cachexia Sarcopenia Muscle 2015;6:99-111.
48. Reid J. Psychosocial, educational and communicative interventions for patients with cachexia and their family carers. Curr Opin Support Palliat Care 2014;8:334-8.
49. Reid J, McKenna H, Fitzsimons D, McCance T. Fighting over food: Patient and family understanding of cancer cachexia. Oncol Nurs Forum 2009;36:439-45.
50. Hopkinson JB. Food connections: A qualitative exploratory study of weight- and eating-related distress in families affected by advanced cancer. Eur J Oncol Nurs 2016;20:87-96.
51. Wheelwright S, Darlington AS, Hopkinson JB, Fitzsimmons D, Johnson C. A systematic review and thematic synthesis of quality of life in the informal carers of cancer patients with cachexia. Palliat Med 2016;30:149-60.
52. Hopkinson JB. The nourishing role: Exploratory qualitative research revealing unmet support needs in family carers of patients with advanced cancer and eating problems. Cancer Nurs 2018;41:131-8.
53. Payne SA, Seymour JE, Chapman A, Holloway M. Older Chinese people’s views on food: Implications for supportive cancer care. Ethn Health 2008;13:497-514.
54. Bell K, Lee J, Ristovski-Slijepcevic S. Perceptions of food and eating among Chinese patients with cancer: Findings of an ethnographic study. Cancer Nurs 2009;32:118-26.
55. Amano K, Morita T, Koshimoto S, Uno T, Katayama H, Tatara R. Eating-related distress in advanced cancer patients with cachexia and family members: A survey in palliative and supportive care settings. Support Care Cancer 2019;27:2869-76.
56. Reid J, McKenna H, Fitzsimons D, McCance T. An exploration of the experience of cancer cachexia: What patients and their families want from health professionals. Eur J Cancer 2010;46:682-9.
57. Dewey A, Dean T. Nurses’ management of patients with advanced cancer and weight loss: Part 2. Int J Palliat Nurs 2008;14:132-8.
58. Millar C, Reid J, Porter S. Healthcare professionals’ response to cachexia in advanced cancer: A qualitative study. Oncol Nurs Forum 2013;40:E393-402.
59. Ferguson ML, Bauer J, Gallagher B, Capra S, Christie DR, Mason BR. Validation of a malnutrition screening tool for patients receiving radiotherapy. Australas Radiol 1999;43:325-7.
60. Schneider CK, Bressler T. Malnutrition screening: An interprofessional approach in outpatient oncology. Clin J Oncol Nurs 2020;24:E28-33.
61. Loeliger J, Dewar S, Kiss N, Drosdowsky A, Stewart J. Patient and carer experiences of nutrition in cancer care: A mixed-methods study. Supp Care Cancer 2021;29:5475-85.
62. Lorton CM, Griffin O, Higgins K, Roulston F, Stewart G, Gough N, et al. Late referral of patients with cancer with malnutrition to dieticians: A prospective study of clinical practice. Supp Care Cancer 2019;28:2351-60.
63. Cook M. Dame Cicely Saunders. Available from: http://mercatornet.com/dame_cicely_saunders. [Last accessed on 2021 Jun 19].